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Abstract. Background: Recently the potential o f magnetic guided biopsies) have been of limited value for diagnosis and
resonance (MR) methods for non-invasive diagnosis and therapy 
evaluation o f prostate cancer has improved substantially, In this 
study proton MR spectroscopy (lH  MRS) was explored for the 
detection o f cancer in the prostate, Patients and Methods: 
Employing an endorectal probe localized JH  MRS and contrast
therapy evaluation of prostate cancer [2], Also MR imaging 
(MRI) is of little use to detect PCa and to determine its 
extent, although the more recent introduction of endorectal 
and body phased-array radiofrequency detection coils have 
enabled better staging of PCa [3,4>5]. The potential of MR
enhanced MR imaging was performed on the prostate o f healthy may be further improved by the use of more adva nced
volunteers and o f patients with benign prostatic hyperplasia 
(BPH) and/or prostate cancer (PCa). Results: !H  MR spectra o f  
the human prostate showed major signals for citrate, creatine 
and choline compounds. For cancer tissue the average 
citrate/choline signal ratio was significantly lower than for BPH
and central zone tissue, butnon-cancerous per 
individual ratios overlapped with ratios for normal central zone 
and BPH tissue, Low citrate/choline ratios in tumour tissue 
correspond with early MR contrast enhancement. Conclusion: 
lH  MRS has potential for non-invasive detection and follow-up 
o f tumours in the prostate.
It is common practice to verify the presence of cancerous 
tissue in the prostate by histology of biopsy material. 
However, this analysis may be subject to sampling errors [1] 
and does not provide much information on spatial 
heterogeneity and multifocality, Non-invasive modalities such 
as computer tomography and transrectal ultrasound (without
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methods such as dynamic Gd contrast enhanced MRI or MR 
spectroscopy (MRS). Several groups have started to perform 
image-guided proton MRS ( 1H MRS) of the human prostate 
with endorectal and/or phase d-array coils [6-9]. In a *H MRS 
examination spectra can be obtained of particular locations 
in the prostate with proton signals of several metabolites. In 
this way it provides a metabolic window on prostate tissue 
which may be used for in situ characterization, diagnosis and 
therapy evaluation of prostate cancer (PCa).
The most prominent metabolite signal in lI i MR spectra of 
the prostate is that of citrate, of which the tissue content has 
been reported as a potential marker to discriminate between
the presence of PCa and benign prostatic 
[10-16], In vitro studies of human prostate specimens have 
demonstrated that the relative intensity of the methyl proton 
signals of (plu)sp.ho)choline compounds in 1H MR spectra of 
PCa tissue is increased [15,16] and our preliminary results 
indicated that this could also be observed in vivo |8],
In this paper we report on results of the application of 
image-guided localized MRS in studies of the prostate of 
healthy volunteers, patients with BPH and/or with PCa. We 
applied and compared single and multiple voxel data 
acquisition methods. As elevation of choline and lowering of 
citrate levels appear to be associated with PCa, the 
citmta/cholhm (Ci/Ch) signal ratio plays a central role in the 
analysis of our data. Preliminary results on the combination 
of *H MRS and dynamic contrast enhanced Gadolinium (Gd) 
MR measurements are also presented.
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Patients and Methods
Volunteers and patients. This study was approved by the local ethical 
committee und informed consent was ob ta ined  from all participants. 
Results o f  studies of 6 healthy volunteers  aging from 32 to 54, without a 
history o r  clinical signs o f  prostate  disease, are included in this report, 
M R  images of the prostates were in terpre ted  as being norma! except for 
some slight hypertrophy of the oldest vo lunteer. Sixteen patients with 
BPH were included in this study (ages be tw een  52 and 73). 
Furtherm ore , 23 patients  suspected to have PCa, mainly on the basis of 
PSA levels (K) ng/ml o r  m ore) and  ultrasonography, w ere  investigated* 
T he  definitive diagnosis (PCa o r  no t)  was m ade  on the basis o f  
histologic til analysis perform ed on  p ro s ta te  tissue specimens obtained by 
needle biopsy or radical prostatectom y. Subjects w ere  positioned supine 
in the magnet bore  with a belt applied a round  the lower abdom en to 
reduce respiratory motion. Patients  received 1 mg glucagon 
intravenously as antiperistaltic drug,
M R methods. M R  examinations w ere  perfo rm ed  on a 1,5 1’ M R  system 
(M agnetom  SP, Siemens, G erm any) em ploying a body radio-frequency 
coil for excitation, For M R  signal reception  a disposable endorectal 
probe ( M E D R A D ^ ,  Pittsburg, U SA ) holding a surface coil, was 
inserted. The probe was inflated with a ir  to ensu re  tight positioning of 
the coil adjacent to  the prostate.
M RI and M R S of the  p rosta te  was perfo rm ed  during the same 
patient exam ination which lasted about 1 hour. First multiple slice M R 
images were obtained in 3 o rthogonal p lanes with a turbo spin-echo 
(TSE) sequence as described previously [5j. G uided  by these images the 
prostate was inspected for the presence of areas likely to contain cancer 
tissue (hypo-intensity in the  periphera l zone and  anatomical deviations), 
Localized ]H M R S was pe rfo rm ed  with a double  sp in-echo slice selective 
pulse sequence (PRESS [17,18]) p receded  by w ater  signal suppression 
which first was turned off to optim ize field homogeneity . The echo-time 
(T e )w as  135 ms.
For single voxel M RS a voxel of nom inal 1.5*1.5* 1.5 cm (3.4 cc) was 
positioned in an  area suspected to be tu m o u r  tissue, find if possible 
ano ther  voxel was studied in a non-cancerous area .,The  scan repetition 
time (Tr) ranged from 1.6 to 4.5 seconds and the n u m b er  of scans from 
96 lo 25 ft.
In the lH M R  spectroscopic imaging (SI) experim ents an axial slab of 
H) mm thickness, 40 (or 50) m m  in the left-right and 30 (or 40) mm in 
the anterior-posterior direction was selected using the PRESS sequence 
(Te =  1 2 0 - 1 3 5  ins) and positioned such that it contained a maximal 
am ount o f  area suspected lo be cancer tissue. G radients  for phase 
encoding in 2 directions were applied Lo obtain  a multiple voxel SI data 
set within this preselected slab [1^,20]. D ata  were encoded  in a 16 * 16 
matrix with a field-of-view of 144 or 160 mm, resulting in nominal voxel 
sizes of 0.8 or 1.0 ec. P er  phase-encoding s tep  2 or 3 acquisitions were 
acquired with a T r  of 1.2 or i.ft seconds resuiting in acquisition times of 
13 - 15 minutes.
For eddy current correction and  referencing purposes MRS 
experiments were also perfo rm ed  with out w ater  suppression.
In a num ber of patients suspected of having PC'a a dynamic Gd 
contrast enhanced  inflow M R  m easu rem en t was perform ed (2 l ,2 2 | after 
the M R S measurements. An axial slice of  10 m m  thickness was selected 
through the suspected tum our region at exactly the sam e location as the
Si slab o r  coinciding with the position of the single voxel. M R  images 
were obtained by a turbo FLA SH  sequence  ( 1 - 2  seconds/image) before 
and during inflow in the slice o f  G d contrast,  which was administered 
intravenously.
Post-processing was perfo rm ed  as described elsewhere [231. 
Metabolite maps were reconstructed  from the intensities of citrate and 
choline proton  signals in SI spectra, showing the spatial distribution of 
these com pounds.
Chemical shifts are given in parts  p e r  million (ppm ) with respect to
the water resonance at 4.68 ppm. Signal integrals were determ ined by 
com puter integration. All presented signal ratios for citrate and choline 
were corrected for Tj weighting using an effective T j  of  33(J ms for 
citrate protons and of 837 ms for choline pro tons as determ ined in a 
separate volunteer study [23]. Average values are presented  with 
standard deviations (± S D ),
Dynamic Gd contrast enhanced M R  experiments are presented as 
dynamic subtraction (DS) images obtained by subtracting M R  images 
recorded during Gd inflow in the slice from control images recorded 
before inflow.
Results
In Figure 1A a T2 weighted MR image is shown of an axial 
plane through the prostate of a patient with PCa. An enlarged 
central gland (BPFI) can be observed as a hypo-intense area 
including some hyper-intense nodular elements. The 
peripheral part of the prostate shows up as a hyper-intense
zone except at the right side on this image where it is hypo-
«
intense (solid box). This area was later demonstrated to be 
tumour tissue by histological examination. It showed earlier 
enhancement than other prostatic tissue on DS MR images 
(see arrow in Figure IB). MRS was performed for voxels 
(see Figure 1A) of which the spectra are shown in figures 1C 
and D. The spectrum in Figure 1C, from a region assumed to 
house no cancer tissue, looks similar to spectra obtained from 
the peripheral zone of normal and most BPH prostates. It 
shows 3 major resonances. One at about 2.6 ppm originating 
from the methylene protons of citrate, one at about 3.0 ppm 
originating from the methyl group of creatine and one at 
about 3.2 ppm to which methyl groups of various choline 
containing compounds contribute. These assignments are 
based on previous MRS studies of perchloric extracts of 
prostate specimens [12-16]. The spectrum from the tumorous 
region (Figure ID) shows a strongly reduced citrate signal 
and an apparently increased choline and decreased creatine 
resonance.
Fifteen patients suspected of having PCa were examined by 
this single voxel approach. Two patients declined further 
medical examination after the MR investigation so that no 
definitive diagnosis is available and 3 were considered to have 
BPH after multiple biopsies. In 10 cases the presence of PCa 
was proven by histopathological examination of prostate 
material, either obtained by biopsy or radical prostatectomy 
[5], After careful evaluation of the MR images and 
comparison with the histopathological results it was 
concluded that in 3 of these cases the voxels, with the aim of 
covering cancer tissue, were either located in an area with no 
apparent presence of cancer tissue or were mostly occupied 
with nan-cancerous tissue (>  75 %). For the 7 remaining 
cases it was estimated that the voxels mainly contained 
tumour tissue (> 50 %). The citrate/choline signal ratio was 
determined from the spectra for further evaluation (see 
below).
In 3 patients suspected of having PCa a dynamic Gd MRI 
measurement was performed after the single voxel *H MRS
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Figure 1. Results o f  an MR examination o f a patient with PC 'a (TM\ PSA 37 nglml).
A. T2 weighted axial TSE image o f  (he prostate. Huws indicate the size and location o f  two selected voxels for h i  MRS. 
H. l)S MR image showing focal enhancement (arrow) due to (id contrast inflow in the tumour. The image is 
start o f  inflow in the imaged slice.
( \ h i  MR spectrum o f  the volume indicated by the ¿lashed box.
I), h i  MR spectrum o f  the volume indicated by the solid box (tumor area),
Ch=Cloline compounds; ('r-creatinc; C/ = citrate.
PPM
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examination showing relative fast enhancement in the area dynamic Gd MR examination arc shown of a PCa patient, 
for which a low Ci/Ch signal ratio was determined.
were
Figure 2a and h show TS weighted MR images of an axial 
slice. Metabolic maps, reconstructed from signals of the vSI 
by 2D SI- in an axial slab through the prostate using similar data set afe overlaid on these images. On the MR image a
voxel hypo-intense area in the peripheral zone is visible (arrow)f  t i M j l V W T M - A  VO as for the
In figure 2 the results of a 2D SI and a extending into the prostate which was later identified as
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Figure 2. Results o f  an MR examination o f a patient with PCa (T3c, 
PSA 19/tgtrnl)
A. 72 weighted axial TSE image o f  the prostate. The coloured overlay 
represents the distribution o f  citrate content over the prostate 
reconstructed from a SI experiment at the same axial location (Te = 120 
mst Tr—1200 ms). A  hypo-intense region in the peripheral zone 
corresponding with tumour tissue is indicated by an arrow.
R  Same Ti weighted image. The coloured overlay now represents 
choline content
C  D S time image showing, early enhancement at the tumour region .
data setvs voxels were selected in identified cancerous areas 
and in areas assumed not to be affected by cancer, Ci/Ch 
signal ratios were determined from the spectra of these
p
voxels.
Although generally the experiments indicate increased 
this area (Figure 2c), choline signals in tumorous regions, in some cases the choline
Of the 8 patients suspected of having PCa and investigated signal actually seemed to be decreased in such regions (with
cancer tissue. The citrate metabolite map (Figure 2a) shows a 
relative low citrate level in this area. In contrast the choline 
metabolite map (Figure 2b) shows increased intensity. 
Furthermore, DS MR images from a dynamic Gd MR 
investigation of the same slice showed fast enhancement in
by SI, 5 were finally diagnosed as having PCa on the basis of 
biopsy material or radical prostatectomy specimens [5], For 1 
patient no final diagnosis could be obtained, while 
histopathological examination of biopsy material from 2 other
respect to the signal of water as an internal reference), but 
because the citrate signal decreased much more, the Ci/Ch 
signal ratio still served as a potential marker of malignancy. 
The plot in Figure 3 summarizes the evaluation of the
patients showed no apparent malignancy. From the five ’SI Ci/Ch signal ratio derived from FI MR spectra of normal
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Citrate/choline signal ratio
P Z y  c z v BPH PZp PCa
Figure -V hrmi,T (7 /C  7; signal integral ratios (±  SI)) obtained from, 
spectra m/ seleitctl tri'it >ns in the prostate.
P / x  ; fH'ttpheml :one norm al prostate o f  volunteers (n=6; method : SI). 
( "Av; ventral ¿unr n o rm a l prostate o f volunteers («=6; m ethod: SI)
I l l ' l l : m w nh  central tf/a /id  (I) PI I region ) o f H PII patients (n =  14: 
method  JS'I .V) /*//» : norm al peripheral zone o f  PCa and BPH patients 
(n ?: m erhtnl: SI )PC \i : malignant tissue ( n -  12; m ethod ; SI and SVS) 
S t  S  -  \m$le vuxvl \[Kttmfrt)seopy 
S I  ® \fm  troMopn im aging
prostates. BPH a n d  PCa patients. It shows the average value 
of this ratio an d  standard deviations obtained from SI
experiments nt th e  normal prostates of healthy volunteers 
(n® 6 ). The Ci/Ch signal ratio value ranges from 2.2 to 5.4 for 
the peripheral / o n e  and from 0.6 to I.(> for the central zone. 
For BPH pa tien ts  (n= l4 )  the Ci/Ch signal ratio was 
determined from single voxel measurements with mainly 
central gland tissue (BPH region) and shows a wide range of 
values; from 0.8 to  7.6. The range of values in non-tumour 
areas ol peripheral zones of PCa and BPH patients
determined with S I  is from 1.7 - 3.5 (n~7).
The average Ci/Ch  signal ratio obtained from all single 
voxel plus SI spec tra  from tumour regions (n=12) is 
significantly low er compared with the other groups:
spectra of the peripheral zone than in spectra of the central 
gland (including the transition zone and periurethral tissue) 
[9,23,24]. This is also evident in this study and is related to 
the different amount of citrate secreting elements in both 
parts of the prostate. The large variation of relative citrate 
signals for central gland BPH tissue is most likely caused by 
differences in glandular and stromal contributions. This study 
shows that decreased relative levels of citrate in cancer tissue 
of the prostate can be detected by in vivo *H MRS. Lower 
citrate levels found in cancerous tissue are presumably due to 
a reduction of citrate secreting epithelial structures [10,14,15].
Results from this and previous studies [8,15,16,24] indicate 
that the choline resonance is increased in cancerous areas of 
the prostate, but occasionally we have also observed reduced 
relative choline signals for PCa tissue in vivo. Elevated signals 
for choline compounds have been reported from *H MRS 
studies of brain tumours [25] and are assumed to be related to 
a high proliferation rate of tumour cells.
The average Tj-corrected citrate/choline signal ratio, which 
we used for quantitative purposes, appears to be significantly 
reduced in tumour tissue compared to normal prostate and 
BPH tissue. However, as there is overlap with values of BPH 
tissue and the normal central zone at the present status of 
MRS, the potential clinical applicability is restricted to 
peripheral zone tumours. The results of this study generally 
are in good agreement with results published recently by 
Kurhanewicz et al [24] employing a similar MRS approach in
3 dimensions.
One cause of the failure to place the volume of interest in a 
malignant region of the prostate by single volume MRS in a 
number of cases is due to the fact that conventional MRI is 
not very reliable in depicting prostate tumours. This shows 
that a multiple volume method for MRS enabling spatial 
evaluation, as efficiently provided by SI methods, is essential. 
Preferentially, spectra should be obtained from voxels 
covering the whole prostate at high spatial resolution [24],
This study also demonstrates that T2-weighted MRI, *H 
MRS and dynamic Gd enhanced MRI can b,e combined in a 
single patient examination. Dynamic Gd enhanced MRI has 
proven to be successful in the detection of some malignancies 
[21]. This is based on the specific (transient) accumulation of 
the contrast compound in tumour tissue related to its typical 
neo-vascular characteristics. Preliminary results indicate that 
it also improves prostate tumour detection (26). H MRSI in 
combination with dynamic Gd contrast enhanced MRI may
peripheral /one, central zone and BPH regions (t tests: p < be helpful to improve the characterization of cancer in 
0,002 for each comparison). However, the range of individual prostate tissue, 
values (11.2-1.2) overlaps with the ratios obtained from central 
zone tissue in norm al prostates and from BPH tissue.
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